Trials / Completed
CompletedNCT01475370
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OCV-501 | 1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001. 2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose. |
Timeline
- Start date
- 2012-01-24
- Primary completion
- 2016-12-22
- Completion
- 2016-12-22
- First posted
- 2011-11-21
- Last updated
- 2021-03-02
- Results posted
- 2021-03-02
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01475370. Inclusion in this directory is not an endorsement.